mecasermin rinfabate inn usan brand name iplex also known drug consisting recombinant human insulinlike growth factor recombinant human insulinlike growth factor binding used treatment amyotrophic lateral sclerosis lou gehrigs similar action mecasermin fewer side effects mecasermin rinfabate developed insmed corporation treatment growth failure children severe primary igfi deficiency primary igfd growth hormone gh gene deletion developed neutralizing antibodies gh due patent settlement iplex taken market short stature related indications however iplex studied treatment several serious medical conditions march fda announced mecasermin rinfabate would made available americans amyotrophic lateral sclerosis als commonly known lou gehrigs disease part clinical trial drug currently available italy iplex investigated phase ii clinical study university rochester school medicine funding provided muscular dystrophy association national institutes health phase ii program studied safety tolerability oncedaily subcutaneous injection iplex patients mmd patients mmd showed significant increases total muscle weight testosterone levels ldl levels significant decreases triglyceride hdl levels functional assays grip strength walk tests show improvement iplex also explored possible therapy hiv associated adipose redistribution syndrome hars data collected phase ii openlabel clinical study directed morris schambelan md professor medicine university california san francisco dr schambelan serves chief endocrinology director general clinical research center san francisco general hospital study designed evaluate safety efficacy iplex treatment primary goal determining effects iplex visceral fat distribution glucose lipid metabolism initial data trial available phase iii trials initiating clinical work earlier stage development iplex treat retinopathy prematurity rop disease affecting estimated premature infants year causes lack development small blood vessels back eye leading blindness majority cases phase clinical study investigating iplex treatment rop initiated university gothenburg sweden collaboration scientists harvard medical school us results study expected end amyotrophic lateral sclerosis als also known lou gehrigs disease progressive neurodegenerative disease affects nerve cells brain spinal cord motor neurons reach brain spinal cord spinal cord muscles throughout body progressive degeneration motor neurons als eventually leads death motor neurons die ability brain initiate control muscle movement lost voluntary muscle action progressively affected patients later stages disease may become totally paralyzed january insmed announced italian ministry health requested insmed corporation make iplex available treat italian patients sufferings als main component iplex subject recent clinical trial als involved people als als treatment centres across united states drug injected skin subcutaneous delivery randomized doubleblinded placebocontrolled trial gold standard way conducting clinical trial end twoyear treatment period differences people als received received placebo muscle strength need tracheostomy breathing survival indicating provided patients benefit current results published november issue researchers led eric j sorenson md mayo clinic rochester minnesota disappointing least definitive gives think pretty definitive answer least strategy drug dr sorenson said however added still great deal evidence pathway beneficial people als way administered novel methods delivering selected fashion way including use viral mediators stem cells two previous phase trials als showed inconsistent results trial carried north america find benefit whereas european trial confirm earlier findings results study resemble previous european study benefit either survival functional scales de sorenson concludes disappointing unable confirm benefit noted previous north american study conclusive evidence points iplex form cant slow progression human als lot sites published articles link lyme disease als sponsored clinics specializing treatment chronic lyme disease sellers products treating myotonia congenita genetic muscle disorder two main types myotonia congenita thomsen disease begins infancy becker disease sometimes called generalized myotonia usually begins ages four httpsenwikipediaorgwikimecaserminrinfabate